Soleno Therapeutics, Inc. (SLNO)
NASDAQ: SLNO · Real-Time Price · USD
79.17
-1.03 (-1.28%)
Jun 13, 2025, 4:00 PM - Market closed
Soleno Therapeutics Employees
Soleno Therapeutics had 92 employees as of December 31, 2024. The number of employees increased by 59 or 178.79% compared to the previous year.
Employees
92
Change (1Y)
59
Growth (1Y)
178.79%
Revenue / Employee
n/a
Profits / Employee
-$2,154,620
Market Cap
3.99B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
SLNO News
- 24 days ago - Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome - GlobeNewsWire
- 26 days ago - Soleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT(TM) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants with Prader-Willi Syndrome - GlobeNewsWire
- 5 weeks ago - Soleno Therapeutics, Inc. (SLNO) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 7 weeks ago - Soleno Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 7, 2025, at 4:30 PM ET - GlobeNewsWire
- 2 months ago - Soleno Therapeutics Announces VYKAT(TM) XR Launch - GlobeNewsWire
- 2 months ago - Soleno Therapeutics Secures FDA Approval For Its First Commercial Drug For Rare Genetic Disorder - Benzinga
- 2 months ago - Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome - GlobeNewsWire